109 related articles for article (PubMed ID: 9645341)
1. Clinical significance of circulating CD44 in non-Hodgkin's lymphoma.
Ristamäki R; Joensuu H; Hagberg H; Kalkner KM; Jalkanen S
Int J Cancer; 1998 Jun; 79(3):221-5. PubMed ID: 9645341
[TBL] [Abstract][Full Text] [Related]
2. Elevated serum levels of soluble CD44 variant 6 are correlated with shorter survival in aggressive non-Hodgkin's lymphoma.
Sasaki K; Niitsu N
Eur J Haematol; 2000 Sep; 65(3):195-202. PubMed ID: 11007056
[TBL] [Abstract][Full Text] [Related]
3. Elevated serum CD44 level is associated with unfavorable outcome in non-Hodgkin's lymphoma.
Ristamäki R; Joensuu H; Lappalainen K; Teerenhovi L; Jalkanen S
Blood; 1997 Nov; 90(10):4039-45. PubMed ID: 9354673
[TBL] [Abstract][Full Text] [Related]
4. Serum CD44 levels preceding the diagnosis of non-Hodgkin's lymphoma.
Mäenpää H; Ristamäki R; Virtamo J; Franssila K; Albanes D; Joensuu H
Leuk Lymphoma; 2000 May; 37(5-6):585-92. PubMed ID: 11042519
[TBL] [Abstract][Full Text] [Related]
5. Serum CD44 in non-Hodgkin's lymphoma.
Ristamäki R; Joensuu H; Jalkanen S
Leuk Lymphoma; 1999 May; 33(5-6):433-40. PubMed ID: 10342571
[TBL] [Abstract][Full Text] [Related]
6. High serum soluble CD44 is correlated with a poor outcome of aggressive non-Hodgkin's lymphoma.
Niitsu N; Iijima K
Leuk Res; 2002 Mar; 26(3):241-8. PubMed ID: 11792412
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of soluble CD44 in patients with breast and colorectal carcinomas and non-Hodgkin's lymphoma.
Lockhart MS; Waldner C; Mongini C; Gravisaco MJ; Casanova S; Alvarez E; Hajos S
Oncol Rep; 1999; 6(5):1129-33. PubMed ID: 10425314
[TBL] [Abstract][Full Text] [Related]
8. Origin and function of circulating CD44 in non-Hodgkin's lymphoma.
Ristämaki R; Joensuu H; Grön-Virta K; Salmi M; Jalkanen S
J Immunol; 1997 Mar; 158(6):3000-8. PubMed ID: 9058839
[TBL] [Abstract][Full Text] [Related]
9. Serum soluble CD27, but not thymidine kinase, is an independent prognostic factor for outcome in indolent non-Hodgkin's lymphoma.
Kok M; Bonfrer JM; Korse CM; de Jong D; Kersten MJ
Tumour Biol; 2003; 24(1):53-60. PubMed ID: 12743427
[TBL] [Abstract][Full Text] [Related]
10. Serum osteopontin and CD44 levels in lymphoreticular malignancies in children.
Elli M; Dagdemir A; Bozkurt C; Pinarli FG; Duzgun A; Ozmen ZC; Ertem U; Acar S
Bratisl Lek Listy; 2012; 113(9):534-8. PubMed ID: 22979908
[TBL] [Abstract][Full Text] [Related]
11. CD44v6 expression in non-Hodgkin's lymphoma: an association with low histological grade and poor prognosis.
Ristamäki R; Joensuu H; Söderström KO; Jalkanen S
J Pathol; 1995 Jul; 176(3):259-67. PubMed ID: 7545748
[TBL] [Abstract][Full Text] [Related]
12. Serum levels and differential expression of CD44 in childhood leukemia and malignant lymphoma: correlation with prognostic criteria and survival.
Taçyildiz N; Cavdar AO; Yavuz G; Gözdaşoglu S; Unal E; Ertem U; Duru F; Ikinciogullari A; Babacan E; Kuzu I; Cin S
Pediatr Int; 2001 Aug; 43(4):354-60. PubMed ID: 11472578
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of serum CD44 measurement in malignant lymphoma.
Fukuda Y
Kurume Med J; 2001; 48(1):65-9. PubMed ID: 11402623
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors in head and neck non-Hodgkin's lymphoma with special reference to serum lactic dehydrogenase and serum copper.
Hisamitsu S; Shibuya H; Hoshina M; Horiuchi J
Acta Oncol; 1990; 29(7):879-83. PubMed ID: 2261202
[TBL] [Abstract][Full Text] [Related]
15. Risk-adjusted prognostic models for Hodgkin's disease (HD) and grade II non-Hodgkin's lymphoma (NHL II): validation on 6728 British National Lymphoma Investigation patients.
Low SE; Horsman JM; Walters SJ; Hancock H; Smith P; Linch D; Hancock BW
Br J Haematol; 2003 Jan; 120(2):277-80. PubMed ID: 12542487
[TBL] [Abstract][Full Text] [Related]
16. [Detection of soluble interleukin-2 receptor in the serum of patients with non-Hodgkin's lymphoma].
Pérez Encinas M; Bello JL; Bendaña A; Rabuñal MJ; González S; Abuín I; Noya M; Cadarso C
Med Clin (Barc); 1998 Jul; 111(5):161-7. PubMed ID: 9732831
[TBL] [Abstract][Full Text] [Related]
17. Advanced diffuse non-Hodgkin's lymphoma. Analysis of prognostic factors by the international index and by lactic dehydrogenase in an intergroup study.
Gordon LI; Andersen J; Colgan J; Glick J; Resnick GD; O'Connell M; Cassileth PA
Cancer; 1995 Feb; 75(3):865-73. PubMed ID: 7530168
[TBL] [Abstract][Full Text] [Related]
18. Elevated serum endostatin is associated with poor outcome in patients with non-Hodgkin lymphoma.
Bono P; Teerenhovi L; Joensuu H
Cancer; 2003 Jun; 97(11):2767-75. PubMed ID: 12767089
[TBL] [Abstract][Full Text] [Related]
19. Circulating intercellular adhesion molecule-1 and its cellular expression in head and neck non-Hodgkin's lymphomas, including lethal midline granuloma.
Harabuchi Y; Kataura A; Imai K
Ann Otol Rhinol Laryngol; 1996 Aug; 105(8):634-42. PubMed ID: 8712635
[TBL] [Abstract][Full Text] [Related]
20. Prognostic parameters in low-grade non-Hodgkin's lymphomas.
Zemunik T; Vucković J; Forenpoher G; Knezević N; Stula N; Dubravcić M; Ribicić I; Rozga A
Neoplasma; 1997; 44(1):13-7. PubMed ID: 9201275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
